Search

Your search keyword '"Murabito, Alessandra"' showing total 34 results
Start Over Author "Murabito, Alessandra"
34 results on '"Murabito, Alessandra"'

1. Contributors

Author

Abbas, Mohammed, primary, Adelani, Isaacson B., additional, Afonso, Gonçalo J.M., additional, Ahmad, Shama, additional, Alberto, González-Zamora, additional, Alikarami, Khashayar, additional, Alva, Ricardo, additional, Amirrajab, Nasrin, additional, Andrade, Paula B., additional, Andreazza, Ana Cristina, additional, Ansari, Amir Chakeri, additional, Aschner, Michael, additional, Ashrafizadeh, Milad, additional, Bagshaw, Olivia R.M., additional, Barbosa, Daniel José, additional, Barroso, Sergio, additional, Bazmi, Amirhossein, additional, Bin Dayel, Faten F., additional, Blanc-Legendre, Mélanie, additional, Boyina, Revathi, additional, Carmo, Helena, additional, Carvalho, Félix, additional, Chadwick, Amy E., additional, Chen, Yi, additional, Convertini, Paolo, additional, Cunha-Oliveira, Teresa, additional, da Costa Silva, Dennis Guilherme, additional, Darroudi, Majid, additional, de Bari, Lidia, additional, de Brum Vieira, Patrícia, additional, De Campos, Opeyemi C., additional, Dehghani, Mohammad Amin, additional, Denslow, Nancy D., additional, Dias, Fernanda Carolina Ribeiro, additional, Dodoala, Sujatha, additional, Drelich, Jaroslaw W., additional, Efraín, Ríos-Sánchez, additional, El Sabbagh, Dana El Soufi, additional, Emmerzaal, Tim L., additional, Farkhondeh, Tahereh, additional, Fernanda, González-Delgado María, additional, Franco, Jeferson Luis, additional, Fromenty, Bernard, additional, Gardner, Georgina L., additional, Garrabou, Glòria, additional, Ghigo, Alessandra, additional, Gindi, Sumalatha, additional, Goldman, Jeremy, additional, Heidari, Reza, additional, Infantino, Vittoria, additional, Jensen, Rebecca L., additional, Kalapos, Miklós Péter, additional, Kiy, Robyn T., additional, Kochi, Camila, additional, Kozicz, Tamas, additional, Lima, Graziela Domingues de Almeida, additional, Lima, Thania Rios Rossi, additional, Lu, Jiawen, additional, Luderer, Ulrike, additional, Machado-Neves, Mariana, additional, Malott, Kelli F., additional, Manuel Oliveira, M., additional, Martyniuk, Christopher J., additional, McDonough, Jennifer, additional, Mendes, Daniela, additional, Moffatt, Chris, additional, Morava, Eva, additional, Murabito, Alessandra, additional, Nie, Chunchao, additional, Niknahad, Hossein, additional, Nunes, Mauro Eugenio Medina, additional, Olawole, Tolulope D., additional, Olesen, Margrethe A., additional, Oliveira, Paulo J., additional, Ommati, Mohammad Mehdi, additional, Peixoto, Francisco, additional, Pereira, Lílian Cristina, additional, Pinho, Sonia L.C., additional, Podinić, Tina, additional, Popolo, Ada, additional, Pourahmad, Jalal, additional, Preston, Graeme, additional, Quintanilla, Rodrigo A., additional, Raha, Sandeep, additional, Rahman, Shamima, additional, Rebeca, Pérez-Morales, additional, Ribeiro, Iara Magalhães, additional, Rizzi, Joyce Santana, additional, Rotimi, Oluwakemi A., additional, Rotimi, Solomon O., additional, Russo, Michele, additional, Sabahi, Ali, additional, Salim, Samina, additional, Samarghandian, Saeed, additional, Santer, Melania, additional, Seloto, Danielle Gabriel, additional, Seydi, Enayatollah, additional, Silva, Mónica G., additional, Simões, Rui F., additional, Souza, Ana Cláudia Ferreira, additional, Sternbach, Sarah, additional, Stuart, Jeffrey A., additional, Talebi, Marjan, additional, Todisco, Simona, additional, Vanani, Atefeh Raesi, additional, and Videira, Romeu A., additional

Published
2023
Full Text
View/download PDF

5. A National Multicenter Study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with Radium-223

Author

Frantellizzi, Viviana, Monari, Fabio, Mascia, Manlio, Costa, Renato, Rubini, Giuseppe, Spanu, Angela, Farcomeni, Alessio, Lodi Rizzini, Elisa, Cindolo, Luca, Murabito, Alessandra, Lavelli, Valentina, Nuvoli, Susanna, Cosma, Laura, Dionisi, Valeria, Nappi, Anna Giulia, Andreola, Marco, and De Vincentis, Giuseppe

Published
2021
Full Text
View/download PDF

13. A PI3Kγ mimetic peptide triggers CFTR gating, bronchodilation, and reduced inflammation in obstructive airway diseases

Author

Ghigo, Alessandra, primary, Murabito, Alessandra, additional, Sala, Valentina, additional, Pisano, Anna Rita, additional, Bertolini, Serena, additional, Gianotti, Ambra, additional, Caci, Emanuela, additional, Montresor, Alessio, additional, Premchandar, Aiswarya, additional, Pirozzi, Flora, additional, Ren, Kai, additional, Della Sala, Angela, additional, Mergiotti, Marco, additional, Richter, Wito, additional, de Poel, Eyleen, additional, Matthey, Michaela, additional, Caldrer, Sara, additional, Cardone, Rosa A., additional, Civiletti, Federica, additional, Costamagna, Andrea, additional, Quinney, Nancy L., additional, Butnarasu, Cosmin, additional, Visentin, Sonja, additional, Ruggiero, Maria Rosaria, additional, Baroni, Simona, additional, Crich, Simonetta Geninatti, additional, Ramel, Damien, additional, Laffargue, Muriel, additional, Tocchetti, Carlo G., additional, Levi, Renzo, additional, Conti, Marco, additional, Lu, Xiao-Yun, additional, Melotti, Paola, additional, Sorio, Claudio, additional, De Rose, Virginia, additional, Facchinetti, Fabrizio, additional, Fanelli, Vito, additional, Wenzel, Daniela, additional, Fleischmann, Bernd K., additional, Mall, Marcus A., additional, Beekman, Jeffrey, additional, Laudanna, Carlo, additional, Gentzsch, Martina, additional, Lukacs, Gergely L., additional, Pedemonte, Nicoletta, additional, and Hirsch, Emilio, additional

Published
2022
Full Text
View/download PDF

15. Sequencing radium 223 and other life-prolonging agents in castration-resistant prostate cancer patients

Author

Caffo, Orazio, primary, Frantellizzi, Viviana, additional, Monari, Fabio, additional, Sbrana, Andrea, additional, Costa, Renato Patrizio, additional, Pinto, Carmine, additional, Tucci, Marcello, additional, Baldari, Sergio, additional, Facchini, Gaetano, additional, Bortolus, Roberto, additional, Alongi, Filippo, additional, Alongi, Pierpaolo, additional, Palermo, Antonio, additional, Fanti, Stefano, additional, Biasco, Elisa, additional, Murabito, Alessandra, additional, Filice, Angelina, additional, Zichi, Clizia, additional, Pignata, Salvatore, additional, Borsatti, Eugenio, additional, Salgarello, Matteo, additional, Spada, Massimiliano, additional, Cortesi, Enrico, additional, and Vincentis, Giuseppe De, additional

Published
2021
Full Text
View/download PDF

17. A National Multicenter Study on overall survival in elderly metastatic castrate-resistant prostate cancer patients treated with Radium-223

Author

Frantellizzi, Viviana, primary, Monari, Fabio, additional, Mascia, Manlio, additional, Costa, Renato, additional, Rubini, Giuseppe, additional, Spanu, Angela, additional, Farcomeni, Alessio, additional, Lodi Rizzini, Elisa, additional, Cindolo, Luca, additional, Murabito, Alessandra, additional, Lavelli, Valentina, additional, Nuvoli, Susanna, additional, Cosma, Laura, additional, Dionisi, Valeria, additional, Nappi, Anna Giulia, additional, Andreola, Marco, additional, and De Vincentis, Giuseppe, additional

Published
2020
Full Text
View/download PDF

19. Radium-223 treatment in castration resistant bone metastatic prostate cancer. Should be the primary tumor always treated?

Author

Serretta, Vincenzo, primary, Valerio, Maria Rosaria, additional, Costa, Renato, additional, Tripoli, Vincenzo, additional, Murabito, Alessandra, additional, Princiotta, Alessandro, additional, Scalici Gesolfo, Cristina, additional, Borsellino, Nicolò, additional, Verderame, Francesco, additional, Gebbia, Vittorio, additional, Licari, Maria, additional, and Sanfilippo, Chiara, additional

Published
2019
Full Text
View/download PDF

20. Autologous peripheral blood mononuclear cells for the treatment of lower extremity lymphedema: A preliminary report.

Author

Bellisi, Mario, Guttuso, Ilenia, Murabito, Alessandra, Corigliano, Alessandro, Filice, Rossella, Trovato, Christian, and Costa, Renato Patrizio

Subjects
MONONUCLEAR leukocytes, LYMPHEDEMA
Abstract

Lymphedema is a chronic devastating disease characterized by the accumulation of fluid in the extremities, tissue progressive changes such as adipose tissue deposition and fibrosis. To restore the functionality and structural integrity of the damaged lymphatic vessels, autologous peripheral blood mononuclear cells (PBMNC) was implanted in 3 sessions, 4 weeks apart, in the affected limb. Each patient was followed for 6 months, monitoring changes in the limb volume. Lymphangiogenesis was evaluated by lymphoscintigraphy, and the monitoring of quality of life. A rapid reduction in the volume of the limbs was observed: Twenty-four point 5 percent of volume reduction after the first implant, 18.5% after the second, and 15.3% at 6 months after the third (p<0.05 vs baseline). Lymphoscintigraphy showed a hyper fixation of the tracer along the ipsilateral iliac axis not appreciable at baseline. Implants of autologous PBMNC in patients with primary lower limb lymphedema seems to be a feasible, effective therapy option. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience.

Author

De Luca, Rossella, Costa, Renato Patrizio, Tripoli, Vincenzo, Murabito, Alessandra, and Cicero, Giuseppe

Subjects
RADIUMTHERAPY, PREDNISONE, DOCETAXEL, ALKALINE phosphatase, BONE metastasis, BONES, CANCER patient psychology, COMBINATION drug therapy, PAIN, PROSTATE tumors, QUALITY of life, TOXICITY testing, TREATMENT effectiveness, RETROSPECTIVE studies
Abstract

Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. Subjects and Methods: In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. Results: Radium-223 was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum ALP levels before and after treatment was observed, with a significant correlation between pain relief and QoL, which showed a value of R2 to 0.44 with a slope of 1.50 (p = 0.0021). Conclusions: Radium-223 showed a clinical benefit, with a reduction in pain symptoms in 58% of patients. Radium-223 was shown to be an effective and well-tolerated therapeutic option in patients with metastatic CRPC progressing after docetaxel plus prednisone treatment. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

32. Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?

Author

Rodolfo Mauceri, Giuseppina Campisi, Maria Licari, A. Princiotta, Antonio Pinto, Renato Costa, Vincenzo Tripoli, Alessandra Murabito, Costa, Renato Patrizio, Tripoli, Vincenzo, Princiotta, Alessandro, Murabito, Alessandra, Licari, Maria, Mauceri, Rodolfo, Campisi, Giuseppina, and Pinto, Antonio

Subjects
lcsh:Medical physics. Medical radiology. Nuclear medicine, Radium-223, medicine.medical_specialty, Bone disease, lcsh:R895-920, Case Report, 030218 nuclear medicine & medical imaging, radium 223, 03 medical and health sciences, Prostate cancer, breast cancer, 0302 clinical medicine, Breast cancer, medicine, Craniofacial, Prospective cohort study, business.industry, Bone metastases, Cancer, medicine.disease, Surgery, Bone metastase, osteonecrosis of the jaw, 030220 oncology & carcinogenesis, business, Osteonecrosis of the jaw, medicine.drug
Abstract

Osteonecrosis of the jaw (ONJ) is a rare and severe necrotic bone disease reflecting a compromise in the body's osseous healing mechanisms and unique to the craniofacial region. Radium 223 dichloride (Ra223) is the only targeted alpha therapy able to extend survival in patients with bone metastases from prostate cancer. Mechanism of action and data currently available focused mainly on osteoblastic metastases from prostate cancer. In 2018, a Caucasian 54-year-old woman presented to our institution for a breast cancer with bone metastases. Since the patient refused any treatment and taking into account the bone disease, our multidisciplinary team evaluated a supplementary strategy with radium 223. A total of six treatments were planned with a dose of 50 KBq/kg every 4 weeks according to Phase 2 data. Four days after the second cycle administration, the patient presented for examination with a self-extracted necrotic bone fragment. Oroantral communication remained in the absence of algic symptomatology or suppuration. The multidisciplinary approach between oncologists, nuclear physicians, and dental health teams is crucial throughout the treatment process to avoid unnecessary suffering in patients at risk. More prospective studies are needed; however, considering the limitation of the present case, radio 223 may play an adjuvant role in the medical treatment of cancer patients with active ONJ.

Published
2019

33. PI3K Signaling in Chronic Obstructive Pulmonary Disease: Mechanisms, Targets, and Therapy

Author

Alessandra Murabito, Flora Pirozzi, Kai Ren, Alessandra Ghigo, Pirozzi, Flora, Ren, Kai, Murabito, Alessandra, and Ghigo, Alessandra

Subjects
Drug, Chronic Obstructive, media_common.quotation_subject, medicine.medical_treatment, Inflammation, targeted therapy, Bioinformatics, Biochemistry, PI3K, Targeted therapy, Pulmonary Disease, 03 medical and health sciences, Phosphatidylinositol 3-Kinases, Pulmonary Disease, Chronic Obstructive, 0302 clinical medicine, Drug Discovery, medicine, COPD, Animals, Humans, Clinical testing, Protein Kinase Inhibitors, PI3K/AKT/mTOR pathway, 030304 developmental biology, Cause of death, media_common, Phosphoinositide-3 Kinase Inhibitors, Pharmacology, 0303 health sciences, Lung, business.industry, Organic Chemistry, medicine.disease, Pathophysiology, respiratory tract diseases, medicine.anatomical_structure, 030228 respiratory system, P13K inhibitors, Signal Transduction, Molecular Medicine, medicine.symptom, business
Abstract

Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory disorder characterized by irreversible chronic inflammation and airflow obstruction. It affects more than 64 million patients worldwide and it is predicted to become the third cause of death in the industrialized world by 2030. Currently available therapies are not able to block disease progression and to reduce mortality, underlying the need for a better understanding of COPD pathophysiological mechanisms to identify new molecular therapeutic targets. Recent studies demonstrated that phosphoinositide 3-kinase (PI3K) signaling is prominently activated in COPD and correlates with an increased susceptibility of patients to lung infections. PI3Ks have thus emerged as promising alternative drug targets for COPD and a wide array of pan-isoform and isoform-selective inhibitors have been tested in preclinical models and are currently being evaluated in clinical studies. Here, we summarize the recent knowledge on the involvement of PI3K enzymes in the pathophysiology of COPD, and we discuss the most recent results arising from the preclinical as well as the clinical testing of PI3K inhibitors as novel therapeutics for COPD.

Published
2017

34. The Clinical Efficacy of Radium-223 for Bone Metastasis in Patients with Castration-Resistant Prostate Cancer: An Italian Clinical Experience

Author

Renato Costa, Alessandra Murabito, Vincenzo Tripoli, Rossella De Luca, Giuseppe Cicero, De Luca, Rossella, Costa, Renato Patrizio, Tripoli, Vincenzo, Murabito, Alessandra, and Cicero, Giuseppe

Subjects
0301 basic medicine, Oncology, Drug, Radium-223, Male, Cancer Research, medicine.medical_specialty, media_common.quotation_subject, Antineoplastic Agents, Bone Neoplasms, Docetaxel, 03 medical and health sciences, Prostate cancer, 0302 clinical medicine, Quality of life, Internal medicine, medicine, Humans, media_common, Aged, Retrospective Studies, Aged, 80 and over, Radioisotopes, business.industry, Bone metastasis, Retrospective cohort study, General Medicine, Middle Aged, medicine.disease, Prostatic Neoplasms, Castration-Resistant, 030104 developmental biology, Italy, 030220 oncology & carcinogenesis, Quality of Life, Alkaline phosphatase, Prednisone, Taxoids, Radium-223 , Bone metastasis , Prostate cancer , Radiopharmaceuticals , Metastatic castration-resistant, prostate cancer ,Quality of Life, business, medicine.drug, Radium
Abstract

Background/Aim: Prostate cancer frequently causes bone metastases and skeletal events that impair quality of life (QoL) and survival. The alpha emitter radium-223 is a new drug that improves treatment in men with castration-resistant prostate cancer (CRPC) and bone metastases. Our aim was to evaluate the effectiveness of radium-223. Subjects and Methods: In this retrospective study we enrolled 48 subjects. Pain reduction, alkaline phosphatase (ALP), time to first symptomatic skeletal event, and QoL were the variables we evaluated. Results: Radium-223 was well tolerated, with a manageable toxicity profile and a modest objective response rate. A considerable difference in serum ALP levels before and after treatment was observed, with a significant correlation between pain relief and QoL, which showed a value of R2 to 0.44 with a slope of 1.50 (p = 0.0021). Conclusions: Radium-223 showed a clinical benefit, with a reduction in pain symptoms in 58% of patients. Radium-223 was shown to be an effective and well-tolerated therapeutic option in patients with metastatic CRPC progressing after docetaxel plus prednisone treatment.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results